TScan Therapeutics, Inc. (TCRX) Misses Q4 EPS by 1c

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q4 EPS of ($0.30), $0.01 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $670 thousand versus the consensus estimate of $1.51 million.

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

You May Also Be Interested In

• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
• Advance Auto Parts falls on revenue miss, weak guidance
• BTCS posts $1.5M gross profit in Q2 2026, net loss widens